GlassScriptPhysician profile
Theodros Mengesha
NPI 1184771909
$24,339.77
in general payments reported to CMS, 2019-2025
56 companies · $4,684 in 2025
The $4,684 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,309 · 2020: $1,792 · 2021: $2,988 · 2022: $3,196 · 2023: $4,365 · 2024: $5,006 · 2025: $4,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $67.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,987.78 |
| Education | $67.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,225.68 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Novartis Pharmaceuticals Corporation | $2,154.50 | 2020-2025 | |
| Biogen, INC. | $1,640.84 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Abbvie INC. | $1,282.46 | 2021-2025 | |
| Sk Life Science, INC. | $1,063.34 | 2021-2025 | |
| Amgen INC. | $1,025.04 | 2019-2025 | Aimovig, Uplizna |
| Pfizer INC. | $929.32 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $906.36 | 2019-2025 | Ultomiris |
| Neurelis, INC. | $868.31 | 2021-2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $835.59 | 2019-2024 | Ajovy, Austedo Xr |
| Acorda Therapeutics, INC | $726.16 | 2019-2023 | Inbrija |
| Lundbeck LLC | $701.01 | 2019-2025 | Vyepti, Rexulti |
| Eisai INC. | $675.89 | 2019-2025 | |
| Argenx US, INC. | $661.83 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Otsuka America Pharmaceutical, INC. | $623.87 | 2023-2025 | Rexulti, Nuedexta |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $534.06 | 2019-2025 | Gamunex-C |
| Genzyme Corporation | $517.44 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $494.25 | 2019-2024 | Qelbree |
| Emd Serono, INC. | $481.59 | 2019-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $476.34 | 2024-2025 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $459.27 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $457.09 | 2022-2025 | Epidiolex |
| Adamas Pharmaceuticals, INC. | $446.27 | 2019-2021 | |
| Mdd US Operations, LLC | $350.92 | 2019-2025 | Gocovri, Apokyn, Gocovri |
| Janssen Pharmaceuticals, INC | $296.34 | 2021-2025 | Spravato, Ponvory |
| Lilly USA, LLC | $293.69 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Celgene Corporation | $206.26 | 2023-2024 | Zeposia |
| Scilex Pharmaceuticals INC. | $203.08 | 2023-2024 | Ztlido |
| Merz Pharmaceuticals, LLC | $202.68 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Sumitomo Pharma America, INC. | $199.26 | 2023-2024 | Aptiom |
| Acadia Pharmaceuticals INC | $192.23 | 2019-2025 | Daybue, Nuplazid |
| Genentech USA, INC. | $184.66 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Janssen Biotech, INC. | $176.82 | 2025 | |
| Tg Therapeutics, INC. | $152.94 | 2023-2025 | |
| Kyowa Kirin, INC. | $98.52 | 2023-2024 | Nourianz |
| Catalyst Pharmaceuticals, INC. | $90.34 | 2023-2025 | Firdapse, Fycompa |
| Axsome Therapeutics, INC. | $85.38 | 2025 | Symbravo |
| Impel Pharmaceuticals INC. | $48.62 | 2022 | |
| Medtronic, INC. | $41.82 | 2025 | Inceptiv |
| Takeda Pharmaceuticals U.S.A., INC. | $41.78 | 2024 | Hyqvia |
| Banner Life Sciences, LLC | $38.42 | 2022-2024 | |
| Allergan, INC. | $29.67 | 2019-2020 | |
| Livanova USA, INC. | $27.04 | 2019-2020 | |
| Aucta Pharmaceuticals, INC. | $23.51 | 2025 | Motpoly Xr |
| Amicus Therapeutics, INC. | $23.25 | 2025 | |
| Averitas Pharma INC. | $20.69 | 2025 | Qutenza |
| Tanabe Pharma America, INC. | $16.94 | 2024 | |
| Vanda Pharmaceuticals INC. | $15.21 | 2024 | Ponvory |
| Amneal Pharmaceuticals LLC | $14.96 | 2023 | Rytary |
| Avion Pharmaceuticals | $14.93 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.80 | 2024 | Wainua |
| Currax Pharmaceuticals LLC | $13.65 | 2021 | |
| Zogenix INC. | $12.60 | 2021 | |
| Assertio Therapeutics, INC. | $11.92 | 2019 | |
| Corium, LLC | $11.33 | 2023 | Adlarity |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodros Mengesha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.